Global Lung Cancer Diagnosis and Therapeutics Industry
New Study on “2018-2023 Lung Cancer Diagnosis and Therapeutics Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast” added to Wise Guy Reports Database
The global lung cancer diagnosis market is anticipated to grow at a CAGR of 7.4% by 2023. Lung cancer occurs when cells of the lung become abnormal and begin to grow out of control. As more cancer cells develop, they form into a tumor and spread to other areas of the body. There are two types of lung cancer; Non-small cell lung cancer (NSCLC) and Small cell lung cancer (SCLC). Several factors such as pollution, smoking, passive smoking and other factors cause lunch cancer. There are several factors that are being considered for the cause of the lung cancer such as rising pollution due to the amount of carbon particles inhaled by humans. Robust healthcare expenditure within the developed countries, increasing pollution, Government initiatives for lung cancer, and rising cases of smoking are some of the major factors that fuel the growth of the market. Several signs and symptoms of lung cancer include coughing up blood, weight loss, chest pain, shortness of breath and others.
Try Sample Report @ https://www.wiseguyreports.com/sample-request/3186926-global-lung-cancer-diagnosis-and-therapeutics-market-research
The lung cancer diagnosis and therapeutics market has been segmented into by type, by treatment, by diagnosis, by stages, and by end user. On the basis type, the market has been bifurcated into non-small cell lung cancer and small cell lung cancer. According to therapy, the market has been bifurcated into chemotherapy, targeted therapy, immunotherapy, radiation therapy and others. Based on diagnosis, the market has been bifurcated into CT-scan, X-rays, lung cancer screening, needle biopsy, bronchoscopy, sputum cytology and others On the basis of end user, the market has been bifurcated into multispecialty hospitals and cancer research centers.
Geographically, the worldwide lung cancer diagnosis and therapeutics showcase is divided into North America, Europe, Asia-Pacific, and Rest of the World. Asia Pacific market is considered to be the fastest growing market globally. The rise in the number of cancer patients in the APAC region is considered to rise eventually enabling the lung cancer diagnosis and therapeutics market to grow. The North America and Europe are considered to be the dominating markets due to various factors such as high healthcare expenditure, development in technology, support from government, rising key players and other factors.
The key players in the lung cancer diagnosis and therapeutics market include Astrazeneca plc, Eli lilly and Sanofi-Aventis, Arqule Inc, Daiichi Sankyo co. Ltd, Celgene, Merck, Pfizer, Ventana, Roche, Genentech, Glaxosmith, Boehringer, Novartis, Bayer, Bristol-Myers Squibb, Eisai, AbbVie, Pharmacyclics.
MARKET SEGMENTATION:
Global lung cancer diagnosis and therapeutics market is segmented on the basis of, type, by therapies, by diagnosis, by end user and regional outlook.
Global Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Type
Global Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Therapies
Global Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Diagnosis
Global Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by End User
Global Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Region
THE REPORTS COVERS:
Comprehensive research methodology of global lung cancer diagnosis and therapeutics
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global lung cancer diagnosis and therapeutics
Insights about market determinants which are stimulating the global lung cancer diagnosis and therapeutics
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
Some points from table of content:
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATES
2.3.2. EUROPEAN UNION
2.3.3. CHINA
2.3.4. INDIA
2.3.5. REST OF THE WORLD
2.4. PATENT ANALYSIS
3. MARKET DETERMINANT
For Detailed Reading Please visit WiseGuy Reports @ https://www.wiseguyreports.com/reports/3186926-global-lung-cancer-diagnosis-and-therapeutics-market-research
3.1. MOTIVATORS
3.1.1. RISING INCIDENCE OF LUNG CANCER
3.1.2. RISING UTILIZATION OF COMBINE THERAPIES FOR TREATMENT OF LUNG CANCER
3.1.3. GOVERNMENT INITIATIVES TO INCREASE AWARENESS FOR LUNG CANCER
3.1.4. RISING POLLUTION DUE TO URBANIZATION INCREASES SYMPTONS OF LUNG CANCER
3.2. RESTRAINTS
3.2.1. HIGH COST ASSOCIATED WITH THERAPIES
3.2.2. ADVERSE EFFECTS OF DRUGS DURING TREATMENT
3.3. OPPORTUNITIES
3.3.1. R&D IN MIXED THERAPIES
3.3.2. STRATEGIC ALLIANCE FOR LATE-STAGE PIPELINE
4. MARKET SEGMENTATION
4.1. GLOBAL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET, BY TYPE
4.1.1. NON-SMALL CELL LUNG CANCER
4.1.1.1. ADENOCARCINOMAS
4.1.1.2. BRONCHIOLOALVEOLAR CARCINOMA
4.1.1.3. SQUAMPOUS CELL CARCINOMA
4.1.1.4. LARGE CELL CARCINOMAS
4.1.2. SMALL CELL LUNG CANCER
4.2. GLOBAL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET, BY THERAPY
4.2.1. CHEMOTHERAPY
4.2.2. TARGETED THERAPY
4.2.3. IMMUNOTHERAPY
4.2.4. RADIATION THERAPY
4.2.5. OTHERS
4.3. GLOBAL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET, BY DIAGNOSIS
4.3.1. CT SCAN
4.3.2. X-RAYS
4.3.3. LUNG CANCER SCREENING
4.3.4. NEEDLE BIOPSY
4.3.5. BRONCHOSCOPY
4.3.6. SPUTUM CYTOLOGY
4.3.7. OTHERS
4.4. GLOBAL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET, BY END USER
4.4.1. MULTISPECIALITY HOSPITALS
4.4.2. CANCER RESEARCH CENTERS
5. COMPETITIVE LANDSCAPE
5.1. STRATEGY ANALYSIS
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ABBVIE
7.2. ARQULE INC.
7.3. ASTRAZENECA PLC
7.4. BAYER
7.5. BOEHRINGER .
7.6. BRISTOL-MYERS SQUIBB
Continued…….
For more information or any query mail at sales@wiseguyreports.com
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn: https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym
Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India
Website: https://www.wiseguyreports.com/sample-request/3186926-global-lung-cancer-diagnosis-and-therapeutics-market-research